Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
Back to Home
A

ARTV

Nasdaq

Artiva Biotherapeutics, Inc.

Latest disclosureOctober 7, 2026
Insider score Why 34?
34/ 100
Qualifying buys · 30d
$0

23 purchases · 17 sales

Price by TradingViewDelayed quote from TradingView, for viewing only. It does not power Whale Atlas scores or alerts. If the quote does not load, open the TradingView link.

Insider transactions 72

Limited filing history
All72Buying23Selling17Other32
Filters

Last 30 daysNo qualifying insider buying. Sales: $981.89K by 4 insiders.

32 of 72 trades · May 11, 2026 – October 6, 2026Incomplete history: this shows the filings imported so far, not every filing ever made. Dates are trade dates. Filters affect this table only.

Showing the first 6 of 32 trades on this page.

Award disclosed

Fred Aslan

Chief Executive Officer

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 15, 2026Filed September 15, 2026SEC filing
Award disclosed

Fred Aslan

Chief Executive Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 15, 2026Filed September 15, 2026SEC filing
Award disclosed

Fred Aslan

Chief Executive Officer

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 10, 2026Filed September 14, 2026SEC filing
Award disclosed

Fred Aslan

Chief Executive Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 10, 2026Filed September 14, 2026SEC filing
Award disclosed

Ra Capital Management +5 more

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 10, 2026Filed September 14, 2026SEC filing
Award disclosed

Laura Stoppel

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 10, 2026Filed September 14, 2026SEC filing
Award disclosed

Elaine K. Sorg

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 10, 2026Filed September 14, 2026SEC filing
Award disclosed

Elizabeth L. Hougen

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 10, 2026Filed September 14, 2026SEC filing
Award disclosed

Brian Daniels

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 10, 2026Filed September 14, 2026SEC filing
Award disclosed

Daniel G. Baker

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 10, 2026Filed September 14, 2026SEC filing
Award disclosed

Alison Moore

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 10, 2026Filed September 14, 2026SEC filing
Award disclosed

Gines Diego Miralles

President & Head of R&D

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 9, 2026Filed September 11, 2026SEC filing
Award disclosed

Gines Diego Miralles

President & Head of R&D

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 9, 2026Filed September 11, 2026SEC filing
Award disclosed

Christopher Horan

Chief Tech Operations Officer

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 9, 2026Filed September 11, 2026SEC filing
Award disclosed

Christopher Horan

Chief Tech Operations Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 9, 2026Filed September 11, 2026SEC filing
Award disclosed

Jennifer Bush

COO, CLO, Compliance Officer

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 9, 2026Filed September 11, 2026SEC filing
Award disclosed

Jennifer Bush

COO, CLO, Compliance Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 9, 2026Filed September 11, 2026SEC filing
Award disclosed

Subhashis Banerjee

Chief Medical Officer

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 9, 2026Filed September 11, 2026SEC filing
Award disclosed

Subhashis Banerjee

Chief Medical Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 9, 2026Filed September 11, 2026SEC filing
Award disclosed

Ra Capital Management +5 more

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 8, 2026Filed September 8, 2026SEC filing
Award disclosed

Laura Stoppel

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 8, 2026Filed September 8, 2026SEC filing
Award disclosed

Elaine K. Sorg

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 8, 2026Filed September 8, 2026SEC filing
Award disclosed

Elizabeth L. Hougen

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 8, 2026Filed September 8, 2026SEC filing
Award disclosed

Brian Daniels

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 8, 2026Filed September 8, 2026SEC filing
Award disclosed

Daniel G. Baker

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 8, 2026Filed September 8, 2026SEC filing
Award disclosed

Alison Moore

Director

Director Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 8, 2026Filed September 8, 2026SEC filing
Exercise or conversion

Subhashis Banerjee

Chief Medical Officer

Common Stock

Value context
$10.19K
Reported price
$1.92 / share
Traded August 27, 2026Filed August 31, 2026SEC filing
Exercise or conversion

Subhashis Banerjee

Chief Medical Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$1.92 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded August 27, 2026Filed August 31, 2026SEC filing
Exercise or conversion

Subhashis Banerjee

Chief Medical Officer

Common Stock

Value context
$823.68
Reported price
$1.92 / share
Traded August 18, 2026Filed August 19, 2026SEC filing
Exercise or conversion

Subhashis Banerjee

Chief Medical Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$1.92 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded August 18, 2026Filed August 19, 2026SEC filing
Award disclosed

Gines Diego Miralles

President & Head of R&D

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 18, 2026Filed May 19, 2026SEC filing
Award disclosed

Gines Diego Miralles

President & Head of R&D

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 18, 2026Filed May 19, 2026SEC filing
Reporting insiderSecurity / transactionAmount / priceValueTraded / disclosedSource
Chief Executive OfficerCommon StockGrant or award110,000Award · no purchase priceNon-cash awardSep 15Filed Sep 15 · 0d laterSEC filing
Chief Executive OfficerEmployee Stock Option (Right to Buy)Grant or awardDerivative units315,000Award · no purchase priceNon-cash awardSep 15Filed Sep 15 · 0d laterSEC filing
Chief Executive OfficerCommon StockGrant or award45,000Award · no purchase priceNon-cash awardSep 10Filed Sep 14 · 4d laterSEC filing
Chief Executive OfficerEmployee Stock Option (Right to Buy)Grant or awardDerivative units155,000Award · no purchase priceNon-cash awardSep 10Filed Sep 14 · 4d laterSEC filing
+5DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units16,250Award · no purchase priceNon-cash awardSep 10Filed Sep 14 · 4d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units16,250Award · no purchase priceNon-cash awardSep 10Filed Sep 14 · 4d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units16,250Award · no purchase priceNon-cash awardSep 10Filed Sep 14 · 4d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units16,250Award · no purchase priceNon-cash awardSep 10Filed Sep 14 · 4d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units16,250Award · no purchase priceNon-cash awardSep 10Filed Sep 14 · 4d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units16,250Award · no purchase priceNon-cash awardSep 10Filed Sep 14 · 4d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units16,250Award · no purchase priceNon-cash awardSep 10Filed Sep 14 · 4d laterSEC filing
President & Head of R&DCommon StockGrant or award45,000Award · no purchase priceNon-cash awardSep 9Filed Sep 11 · 2d laterSEC filing
President & Head of R&DEmployee Stock Option (Right to Buy)Grant or awardDerivative units135,000Award · no purchase priceNon-cash awardSep 9Filed Sep 11 · 2d laterSEC filing
Chief Tech Operations OfficerCommon StockGrant or award40,000Award · no purchase priceNon-cash awardSep 9Filed Sep 11 · 2d laterSEC filing
Chief Tech Operations OfficerEmployee Stock Option (Right to Buy)Grant or awardDerivative units120,000Award · no purchase priceNon-cash awardSep 9Filed Sep 11 · 2d laterSEC filing
COO, CLO, Compliance OfficerCommon StockGrant or award45,000Award · no purchase priceNon-cash awardSep 9Filed Sep 11 · 2d laterSEC filing
COO, CLO, Compliance OfficerEmployee Stock Option (Right to Buy)Grant or awardDerivative units135,000Award · no purchase priceNon-cash awardSep 9Filed Sep 11 · 2d laterSEC filing
Chief Medical OfficerCommon StockGrant or award30,000Award · no purchase priceNon-cash awardSep 9Filed Sep 11 · 2d laterSEC filing
Chief Medical OfficerEmployee Stock Option (Right to Buy)Grant or awardDerivative units85,000Award · no purchase priceNon-cash awardSep 9Filed Sep 11 · 2d laterSEC filing
+5DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units13,750Award · no purchase priceNon-cash awardSep 8Filed Sep 8 · 0d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units13,750Award · no purchase priceNon-cash awardSep 8Filed Sep 8 · 0d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units13,750Award · no purchase priceNon-cash awardSep 8Filed Sep 8 · 0d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units13,750Award · no purchase priceNon-cash awardSep 8Filed Sep 8 · 0d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units13,750Award · no purchase priceNon-cash awardSep 8Filed Sep 8 · 0d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units13,750Award · no purchase priceNon-cash awardSep 8Filed Sep 8 · 0d laterSEC filing
DirectorDirector Stock Option (Right to Buy)Grant or awardDerivative units13,750Award · no purchase priceNon-cash awardSep 8Filed Sep 8 · 0d laterSEC filing
Chief Medical OfficerCommon StockOption exercise or conversion10b5-15,306$1.92 / share$10.19KAug 27Filed Aug 31 · 4d laterSEC filing
Chief Medical OfficerEmployee Stock Option (Right to Buy)Option exercise or conversion10b5-1Derivative units5,306$1.92 exercise / conversion priceNot a separate purchaseAug 27Filed Aug 31 · 4d laterSEC filing
Chief Medical OfficerCommon StockOption exercise or conversion10b5-1429$1.92 / share$823.68Aug 18Filed Aug 19 · 1d laterSEC filing
Chief Medical OfficerEmployee Stock Option (Right to Buy)Option exercise or conversion10b5-1Derivative units429$1.92 exercise / conversion priceNot a separate purchaseAug 18Filed Aug 19 · 1d laterSEC filing
President & Head of R&DCommon StockGrant or award77,500Award · no purchase priceNon-cash awardMay 18Filed May 19 · 1d laterSEC filing
President & Head of R&DEmployee Stock Option (Right to Buy)Grant or awardDerivative units232,500Award · no purchase priceNon-cash awardMay 18Filed May 19 · 1d laterSEC filing

Congress transactions 0

All Congress filings
No disclosed congressional trades for ARTV in the imported filings.

This reflects the filings imported so far, not a complete trading history.

Explore furtherTechnical lab Company financials Test a strategy Compare company

Why this buying score?

Qualifying common-equity purchase value

$28,803,280 of common-equity purchase value after transaction-age decay across 180 days.

+25 pts

Distinct buying groups

2 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.

+6 pts

Material reported holdings increase

At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.

+3 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage
Source
SEC EDGAR · Form 4
Issuer CIK
0001817241
Latest public acceptance
Oct 7, 2026, 08:02 PM UTC
Score calculated
Oct 8, 2026, 12:09 AM UTC
Parser
form4-parser-1.5
Classifier
form4-classifier-1.1
Scoring methodology
insider-experimental-1.1
Availability
Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.